ImpriMed, Inc.

ImpriMed, founded in 2017, is a leading AI-driven precision medicine startup revolutionizing cancer treatment with its advanced drug response prediction technology. ImpriMed's core service, the Personalized Prediction Profile, harnesses the power of AI to provide tailored treatment strategies for pets with blood cancers. This service has been used by hundreds of veterinary oncologists nationwide, contributing to the assessment and treatment of over 6,000 dogs with lymphoma or leukemia. ImpriMed's precision oncology results have been recognized in four peer-reviewed scientific journals and have influenced over 250 veterinary hospitals in the US. Our personalized medicine services can help create treatment plans and save precious time for pets with lymphoma and leukemia. Please visit our booth for more information.